BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.
Vittorio StefoniLisa ArgnaniMatteo CarellaBeatrice CasadeiAlice MorigiGinevra LolliAlessandro BroccoliCinzia PellegriniLaura NanniPaolo Elia CoppolaPier Luigi Luigi ZinzaniPublished in: Journal of cancer research and clinical oncology (2022)
BEGEV regimen was well tolerated, and reversible haematological toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells.